Anixa Biosciences, Inc. (NASDAQ:ANIX – Get Rating)’s share price rose 3.2% during mid-day trading on Friday . The company traded as high as $5.04 and last traded at $4.90. Approximately 34,965 shares were traded during mid-day trading, a decline of 58% from the average daily volume of 83,798 shares. The stock had previously closed at $4.75.
Anixa Biosciences Stock Up 3.2 %
The stock has a 50 day moving average price of $5.11 and a 200 day moving average price of $4.09. The stock has a market capitalization of $150.23 million, a price-to-earnings ratio of -10.43 and a beta of 1.14.
Anixa Biosciences (NASDAQ:ANIX – Get Rating) last announced its quarterly earnings results on Friday, September 9th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.04. Sell-side analysts forecast that Anixa Biosciences, Inc. will post -0.51 earnings per share for the current fiscal year.
Institutional Trading of Anixa Biosciences
Anixa Biosciences Company Profile
Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain protein functions of the virus.
- Get a free copy of the StockNews.com research report on Anixa Biosciences (ANIX)
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
- How High Can the Fed Go? How to Trade it
- Verra Mobility Stock Has Returned Back to the Station
- Does ASML’s November Rally Have Staying Power?
Receive News & Ratings for Anixa Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anixa Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.